| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
24,981 |
20,066 |
$1.16M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,262 |
5,337 |
$478K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
6,135 |
5,491 |
$380K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
4,503 |
4,133 |
$322K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
5,432 |
4,552 |
$318K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
2,399 |
2,194 |
$190K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,926 |
2,282 |
$91K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,768 |
2,495 |
$83K |
| 90686 |
|
4,579 |
4,250 |
$68K |
| 96127 |
|
11,753 |
9,845 |
$49K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
4,338 |
2,662 |
$47K |
| 99460 |
|
785 |
728 |
$45K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,776 |
2,333 |
$39K |
| 92551 |
|
4,240 |
3,842 |
$37K |
| 90670 |
|
2,705 |
2,435 |
$32K |
| 90680 |
|
2,361 |
2,089 |
$30K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
656 |
564 |
$25K |
| 90698 |
|
2,074 |
1,899 |
$24K |
| 90633 |
|
1,752 |
1,560 |
$23K |
| 90651 |
|
1,333 |
1,196 |
$19K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
219 |
185 |
$18K |
| 90697 |
|
1,083 |
899 |
$17K |
| 99173 |
|
6,427 |
5,820 |
$13K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,091 |
884 |
$12K |
| 99051 |
|
953 |
857 |
$12K |
| 90744 |
|
950 |
851 |
$12K |
| 83655 |
|
1,702 |
1,536 |
$11K |
| 99174 |
|
2,398 |
2,166 |
$10K |
| 90671 |
|
792 |
639 |
$9K |
| 96161 |
|
3,279 |
2,673 |
$9K |
| 90619 |
|
476 |
393 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,325 |
603 |
$8K |
| 87634 |
|
153 |
144 |
$7K |
| 0071A |
|
227 |
183 |
$7K |
| 0072A |
|
191 |
166 |
$6K |
| 90672 |
|
337 |
321 |
$6K |
| 99383 |
|
52 |
49 |
$5K |
| 90710 |
|
399 |
368 |
$5K |
| 90696 |
|
377 |
353 |
$5K |
| 90716 |
|
368 |
324 |
$5K |
| 90707 |
|
399 |
356 |
$4K |
| 96160 |
|
1,592 |
1,395 |
$4K |
| 90656 |
|
242 |
242 |
$4K |
| 90480 |
|
163 |
144 |
$4K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,327 |
1,159 |
$4K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
153 |
76 |
$3K |
| 90734 |
|
249 |
240 |
$3K |
| 99384 |
|
26 |
26 |
$3K |
| 99382 |
|
45 |
32 |
$3K |
| 85018 |
|
1,742 |
1,534 |
$3K |
| 0002A |
|
113 |
103 |
$2K |
| 90621 |
|
128 |
117 |
$2K |
| 90715 |
|
164 |
147 |
$2K |
| 0001A |
|
151 |
117 |
$2K |
| 90677 |
|
96 |
92 |
$2K |
| 0004A |
|
45 |
36 |
$1K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
15 |
15 |
$1K |
| 0054A |
|
65 |
41 |
$1K |
| 99050 |
|
78 |
74 |
$1K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
589 |
578 |
$1K |
| 99188 |
|
55 |
55 |
$1K |
| 0124A |
|
30 |
29 |
$1K |
| 91318 |
|
63 |
55 |
$825.49 |
| 87807 |
|
225 |
210 |
$675.46 |
| 91320 |
|
12 |
12 |
$602.20 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
65 |
64 |
$490.00 |
| 0082A |
|
12 |
12 |
$480.00 |
| 0011A |
|
44 |
37 |
$440.00 |
| 81002 |
|
345 |
289 |
$423.17 |
| 90660 |
|
17 |
17 |
$331.05 |
| 90685 |
|
552 |
496 |
$331.05 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
50 |
40 |
$261.03 |
| 90688 |
|
23 |
13 |
$234.39 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
14,658 |
9,307 |
$216.72 |
| 0074A |
|
16 |
15 |
$200.00 |
| 99499 |
|
24 |
12 |
$149.00 |
| 90461 |
|
8,235 |
4,202 |
$116.70 |
| 96380 |
|
15 |
12 |
$87.08 |
| 36416 |
|
2,182 |
1,755 |
$67.50 |
| 90473 |
|
64 |
63 |
$20.00 |
| 81003 |
|
12 |
12 |
$11.24 |
| 91307 |
|
558 |
434 |
$0.83 |
| 91308 |
|
93 |
84 |
$0.51 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
14 |
13 |
$0.40 |
| 91305 |
|
127 |
85 |
$0.37 |
| 91312 |
|
30 |
29 |
$0.13 |
| 0012A |
|
23 |
23 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
16 |
14 |
$0.00 |
| G9920 |
Screening performed and negative |
6,368 |
5,717 |
$0.00 |
| 99072 |
|
359 |
322 |
$0.00 |
| 91300 |
|
233 |
199 |
$0.00 |